Explore

Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Trendline Trendline
Enveric Biosciences Reports First Quarter 2026 Financial Results and Advances Drug Development

Enveric Biosciences Reports First Quarter 2026 Financial Results and Advances Drug Development

Enveric Biosciences Reports First Quarter 2026 Financial Results and Advances Drug Development
Trendline Trendline
Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate
Trendline Trendline
Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep for Securities Violations

Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep for Securities Violations

Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep for Securities Violations
Trendline Trendline
Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss
Trendline Trendline
Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses
Trendline Trendline
NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements
Trendline Trendline
Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026

Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026

Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026
Trendline Trendline
Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase
Trendline Trendline
Brainstorm Cell Therapeutics Reports Narrowed Loss in Q1 2026 Amid Clinical Developments

Brainstorm Cell Therapeutics Reports Narrowed Loss in Q1 2026 Amid Clinical Developments

Brainstorm Cell Therapeutics Reports Narrowed Loss in Q1 2026 Amid Clinical Developments
Trendline Trendline
Alpha Cognition Reports Strong Q1 2026 Financial Results and Operational Progress

Alpha Cognition Reports Strong Q1 2026 Financial Results and Operational Progress

Alpha Cognition Reports Strong Q1 2026 Financial Results and Operational Progress
Trendline Trendline
NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials

NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials

NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials